poster presentation abstracts

voriconazole is the first-line therapy for invasive aspergillosis. nevertheless, mortality remains high due to different factors. although azoles are very active in vitro against aspergillus fumigatus, several studies have reported azole-resistant a. fumigatus isolates in european countries, asia, and the united states. therefore, new approaches are needed. the aim of the present study was to evaluate the in vitro combination of micafungin with voriconazole as currently used antifungal drug against azole-resistant a. fumigatus with various point mutations from clinical and environmental sources